Search This Blog

Friday, December 20, 2019

FDA OKs expanded label of DexCom’s G5 CGM

The FDA approves the use of DexCom’s (NASDAQ:DXCM) G5 Mobile Continuous Glucose Monitoring (CGM) System for diabetes treatment decisions without the need for a confirmation test via fingerstick sample.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)